Recent Updates
Recently added Catalysts

Avalyn Pharma Inc.

AVLNFDA catalysts, PDUFA dates & pipeline intelligence
$29.76
▼ -0.52 · -1.72%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full AVLN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $25.0552W HIGH $32.23
Volume
329.07 K
Value Traded
9.86 M
Short % Float
8.61%
Days to Cover
5.3
-4.52%Week
+27.56%1 Month
-23.42%3 Month
+5.87%6 Month
+10.92%5 Year
+10.92%All Time

Cash Data

Unlock AVLN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.32 B
EPS (TTM)
-
P/E Ratio
-
Ent. Value
953.18 M
Total Shares
44.52 M
Float Shares
26.75 M
Insiders
39.92%
Institutions
69.81%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2b topline data readout
AP01 (inhaled pirfenidone)
progressive pulmonary fibrosis (PPF)
Phase 2bSmall MoleculesRespiratory
Unlock every AVLN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

AVLN Catalyst Timeline

Dated clinical, regulatory and corporate events for Avalyn Pharma Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Avalyn Pharma Inc.

29Total events
10Upcoming
3Tier-1 (high impact)
2026 to 2029Coverage

Upcoming catalysts 2

T2Timing Guidance
Subscribe to view catalyst details
AP02
T1Topline Readout
Subscribe to view catalyst details
AP01

Event history 14

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Topline ReadoutAP02Clinical Data
Avalyn publishes Phase 1 data for AP02 highlighting lung-targeted delivery and safety profile
idiopathic pulmonary fibrosissource ↗
▲PublicationAP02Presentation
AP02 Phase 1 data published in Respiratory Research
idiopathic pulmonary fibrosissource ↗
●Management ChangeCorporate
Robert J. Meyer, MD appointed to Board of Directors
●Poster PresentationAP01Presentation
AP01 lung distribution modeling data presented at ERS Congress 2026
pulmonary fibrosissource ↗
●Poster PresentationPresentation
Patient survey on IPF clinical trial participation presented at ERS Congress 2026
idiopathic pulmonary fibrosissource ↗
▲Poster PresentationAP01Presentation
AP01 lung distribution modeling data presented at ERS Congress 2026
pulmonary fibrosissource ↗
●Poster PresentationPresentation
Patient survey on IPF clinical trial participation preferences presented at ERS Congress 2026
idiopathic pulmonary fibrosissource ↗
●Oral PresentationAP01Presentation
AP01 modeling and patient survey data presented at ERS International Congress 2026
pulmonary fibrosissource ↗
●Poster PresentationAP01Presentation
Presented two AP01 posters at ERS Congress in Barcelona
idiopathic pulmonary fibrosissource ↗
Unlock the full AVLN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How AVLN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all AVLN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 57%
Micro Cap
(rank 414 of 725)
Percentile Rank
Showing 3 of 3 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
AP01 Small MoleculesNCT06329401Pulmonary FibrosisPhase 2 ACTIVE NOT_RECRUITING 398Jun 1, 2027
AP01 Small MoleculesNCT06951217Progressive Pulmonary FibrosisPhase 2 RECRUITING 340Dec 31, 2031
AP02 Small MoleculesNCT07194382Idiopathic Pulmonary Fibrosis (IPF)Phase 2 RECRUITING 160Jun 1, 2027
Unlock the AVLN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every AVLN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
AP01 progressive pulmonary fibrosisPhase 2b2026-05-06encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidoneRead MoreAvalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International ConferenceRead More
Scroll for more · summaries link to the source press release
Unlock every AVLN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock AVLN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
FMR LLC10% Owner, See Remark 1Sell -5,565 2,103,970 held$29.56 11/10/2026
Unlock the full AVLN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PERCEPTIVE ADVISORS LLC 1.3 % 76.22 M 2.68 M
Unlock every fund holding AVLN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in AVLN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see AVLN ownership
Insider and institutional ownership, quarter by quarter.

AVLN Short Interest

Shares sold short, counted twice a month.

8.61%
Short % of Float
of tradable shares sold short
2.3M
Shares Sold Short
-2.2% vs prior count
5.3 High
Days to Cover
trading days of normal volume to buy every short share back
434.3K
Avg Daily Volume
the average used for days to cover
Unlock AVLN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock AVLN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live AVLN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock AVLN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How AVLN ranks across every disease it competes in

Competitive Position is a premium feature
See how AVLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

AVLN News

AVLN
Nov 12, 2026
AVLNGeneral

Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma reported its third quarter 2026 financial results, highlighting the initiation of a Phase 1 study for AP03, a combination therapy. The company presented promising data for AP01 and AP02 at the ERS Congress. With $386.6 million in cash, Avalyn is well-positioned to advance its pipeline into 2029.

Read more →
AVLN
Nov 3, 2026
AVLNConferences/Events

Avalyn to Present at Upcoming Investor Conferences

Avalyn Pharma Inc. announced its participation in several upcoming investor conferences, including the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. The company is advancing inhaled therapies for serious respiratory diseases, with promising results from its clinical trials for AP01 and AP02 programs. These efforts aim to improve treatment outcomes for pulmonary fibrosis.

Read more →
AVLN
Sep 21, 2026
AVLNPhases

Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile

Avalyn has published Phase 1 data showcasing the effectiveness of AP02 in delivering antifibrotic medicines directly to the lungs. This approach aims to enhance local exposure while minimizing systemic effects, leading to improved tolerability. The findings support further development of AP02 for treating idiopathic pulmonary fibrosis, with ongoing patient enrollment.

Read more →
AVLN
Sep 16, 2026
AVLNGeneral

Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors

Avalyn Pharma has appointed Dr. Robert J. Meyer to its Board of Directors. Dr. Meyer, a seasoned pulmonary physician and former FDA leader, brings over 25 years of experience in regulatory and clinical development. His expertise is expected to guide Avalyn's ongoing clinical programs, including AP01 and AP02, aimed at treating serious respiratory diseases. The company is focused on transforming treatment paradigms for pulmonary fibrosis through innovative inhaled therapies.

Read more →
AVLN
Sep 8, 2026
AVLNConferences/Events

Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis

Avalyn Pharma presented new data at the ERS International Congress 2026, highlighting the predicted aerosol distribution of their inhaled therapy AP01 in both healthy and severely fibrotic lungs. The findings emphasize the importance of patient perspectives in clinical trial design, revealing a strong willingness among patients with idiopathic pulmonary fibrosis to participate in research. The data supports the potential for AP01 to deliver effective treatment directly to areas impacted by disease.

Read more →
AVLN
Sep 8, 2026
AVLNConferences/Events

Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Avalyn Pharma Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026. The company focuses on developing inhaled therapies for serious respiratory diseases, including pulmonary fibrosis. Their AP01 and AP02 programs are currently in clinical trials, showcasing promising results in safety and efficacy.

Read more →
AVLN
Aug 24, 2026
AVLNConferences/Events

Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026

Avalyn Pharma will present two posters at the European Respiratory Society International Congress 2026 in Barcelona. The presentations cover patient perspectives on clinical trial design and in silico modeling of its AP01 formulation. These sessions highlight the company's focus on integrating patient input and predicting lung distribution for its inhaled therapies. The event takes place from September 5 to 9, 2026.

Read more →
AVLN
Aug 12, 2026
AVLNPhases
▲ +5.4%on this news

Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma completed enrollment of its MIST global Phase 2b trial for AP01 with 398 patients. Topline data from this study is expected in the second half of 2027. The company ended the second quarter of 2026 with $413.5 million in cash and marketable securities. This balance is projected to fund operations into 2029.

Read more →
AVLN
Jun 17, 2026
AVLNPhases

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

Avalyn Pharma has successfully completed target enrollment of 375 patients for the Phase 2b MIST trial evaluating AP01, an inhaled formulation of pirfenidone for progressive pulmonary fibrosis (PPF). The trial aims to assess the safety and efficacy of AP01 compared to a placebo over 52 weeks. Topline results are anticipated in the second half of 2027, and the company expresses optimism about the potential benefits of AP01 based on previous clinical data.

Read more →
AVLN
Jun 3, 2026
AVLNGeneral

Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights

Avalyn Pharma reported its Q1 2026 financial results, highlighting progress in its clinical trials for inhaled therapies targeting pulmonary fibrosis. The company is on track to complete enrollment in the MIST Phase 2b trial of AP01 by mid-2026 and has initiated the AURA Phase 2 trial for AP02. Following a successful IPO, Avalyn has sufficient funds to support its operations through 2029. The company aims to redefine treatment standards for serious respiratory diseases.

Read more →
AVLN
May 27, 2026
AVLNConferences/Events

Avalyn to Participate in the Jefferies Global Healthcare Conference

Avalyn Pharma Inc. will present a company overview at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will highlight Avalyn's innovative inhaled therapies aimed at treating serious respiratory diseases, particularly their ongoing clinical trials for pulmonary fibrosis. The company is focused on transforming treatment paradigms with optimized formulations of established antifibrotic medicines.

Read more →
AVLN
May 21, 2026
AVLNConferences/Events

Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026

Avalyn Pharma Inc. announced that it will present updated long-term data on AP01, an inhaled formulation of pirfenidone, at the EULAR 2026 conference. The findings from the ATLAS trial will focus on the drug's tolerability in patients with progressive pulmonary fibrosis over four years. This presentation aims to highlight the potential benefits of inhaled therapies for serious respiratory diseases.

Read more →
AVLN
May 6, 2026
AVLNConferences/Events

Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference

Avalyn Pharma will present patient-centered research at the ATS 2026 International Conference, focusing on inhaled therapies for pulmonary fibrosis. The presentations include findings from a usability study of the eFlow® Nebulizer System and patient perspectives on supportive healthcare experiences. Avalyn aims to enhance treatment through direct patient input and innovative inhaled formulations.

Read more →
AVLN
May 4, 2026
AVLNGeneral

Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Avalyn Pharma Inc. has successfully closed its initial public offering, raising $345 million through the sale of 19,166,667 shares at $18.00 each. The offering included the full exercise of an overallotment option by underwriters. The company's stock is now listed on the Nasdaq Global Select Market under the ticker AVLN.

Read more →

About Avalyn Pharma Inc.

Boston, MA avalynpharma.com
Headquarters105 W FIRST ST., BOSTON, MA, 02127
Founded2011
BIOPHARMAWATCH ELITE
Trade the next AVLN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime